Do catastrophic costs impact treatment outcomes in people with rifampicin-resistant tuberculosis in the Republic of Moldova?

Do catastrophic costs impact treatment outcomes in people with rifampicin-resistant tuberculosis in the Republic of Moldova?

The Republic of Moldova is among the 30 Rifampicin-Resistant and/or Multidrug-Resistant (RR/MDR) Tuberculosis (TB) high burden countries in the world. Despite free TB diagnostics and treatment, TB patients face substantial economic losses and this may impact overall treatment outcomes. We assessed...

Full description

Bibliographic Details
Main Authors: Valeriu Plesca, Ana Ciobanu, Yuliia Sereda, Andrei Dadu
Format: Article
Language:English
Published: PAGEPress Publications 2021-01-01
Series:Monaldi Archives for Chest Disease
Subjects:
Multidrug-resistant tuberculosis
catastrophic cost
treatment outcome
Republic of Moldova
SORT-TB
Online Access:https://monaldi-archives.org/index.php/macd/article/view/1650

Internet

https://monaldi-archives.org/index.php/macd/article/view/1650

Similar Items